Skanska signs additional contract for biotechnology facility in Charlottesville, USA, for USD 116M, about SEK 1.2 billion
Comunicato Precedente
Comunicato Successivo
The building will include modular, multi-use laboratory space and support space, expanded research facilities, core facilities and an area for 100-150 researchers and partnering biotechnology companies to foster collaboration on the frontlines of science and technology.
Construction began in December 2023 and is expected to be completed in the fourth quarter of 2027.
For further information please contact:
Ashley Jeffery, Communications Director,
USA Building, tel +1 813 459 3682
Andreas Joons, Press Officer, Skanska Group, tel +46 (0)10 449 04 94
Direct line for media, tel +46 (0)10 448 88 99
This and previous releases can also be found at www.skanska.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/skanska/r/skanska-signs-additional-contract-for-biotechnology-facility-in-charlottesville--usa--for-usd-116m--,c4233874
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/skanska-signs-additional-contract-for-biotechnology-facility-in-charlottesville-usa-for-usd-116m-about-sek-1-2-billion-302556037.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




